Margaret Hoffmanterry
Infectious Disease · Allentown, PANPI 1821027467
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $86,165 of the $124,886 with a category attached, or 69.0%. Viiv Healthcare Company accounts for 69.4% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2019 at $58,389 and has fallen 99.1% since, to $499 in 2025. Among infectious disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 138 payments — averaging $904.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$87K
- Gilead$38K
Across 64 payments — averaging $4649.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$270K
- GSK$26K
- Merck$1K
What the payments were for
- Consulting fees$26,68021%
- Speaking & faculty fees$86,16569%
- Travel & lodging$9,1097%
- Food & beverage$2,9332%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 90 | $86,638 |
| Gilead | 48 | $38,248 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$124,886 in reported general payments places this provider in the 95th percentile of 457 infectious disease providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 629 | $2,397,911 |
| JulucaDolutegravir/Rilpivirine | 146 | $491,684 |
| CabenuvaCabotegravir/Rilpivirine | 63 | $362,456 |
| TivicayDolutegravir Sodium | 138 | $292,680 |
| DescovyEmtricitabine/Tenofov Alafenam | 91 | $206,473 |
| DovatoDolutegravir Sodium/Lamivudine | 71 | $198,126 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 43 | $187,182 |
| PifeltroDoravirine | 94 | $177,017 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 34 | $113,135 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 30 | $107,274 |
| PrezcobixDarunavir/Cobicistat | 44 | $102,513 |
| EnbrelEtanercept | 13 | $97,831 |
| IsentressRaltegravir Potassium | 44 | $84,718 |
| OzempicSemaglutide | 89 | $81,805 |
| XifaxanRifaximin | 19 | $56,643 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $38,248 | $2,711,659750 claims |
| Viiv Healthcare CompanyJuluca, Cabenuva, Tivicay, Dovato, Triumeq | $86,638 | $1,398,383434 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 457 infectious disease providers in Pennsylvania.
Other infectious disease in Allentown
- David HornPhiladelphia$2.1M
- Judith WolfPhiladelphia$1.2M
- Karam MounzerPhiladelphia$712K
- William ShortPhiladelphia$520K
- David WuWest Chester$483K
- William PaceSouthampton$472K
- Amesh AdaljaPittsburgh$415K
- Brett GilbertWynnewood$352K
- Timothy BabinchakPhoenixville$311K
- Tuesdae Stainbrookdu Bois$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.